about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Drug com­pa­nies reach $260M set­tle­ment just ahead of opi­oid tri­al; Oys­ter Point set terms for $85M IPO

6 years ago
News Briefing

Ronald Herb­st fol­lows Med­Im­mune ex­o­dus to Pyx­is CSO post; Jeff God­dard to suc­ceed CEO of AIT Bio­science

6 years ago
Peer Review

FDA re­quests ad­di­tion­al time for Flex­ion's sN­DA; Genen­tech re­leas­es da­ta for PhI­II study of Rit­ux­an

6 years ago
News Briefing

North­west Bio still hang­ing on; Five Prime's lat­est round of lay­offs claims 70

6 years ago
News Briefing

Zosano Phar­ma CEO pass­es ba­ton down to suc­ces­sor; James Sapirstein takes the helm at Azur­Rx

6 years ago
Peer Review

Pro­lif­ic In­sil­i­co scores up to $200M deal in Chi­na; Re­searchers re­tract pa­per on gene in­volved in CRISPR ba­by ...

6 years ago
News Briefing

FDA ap­proves drug for rare con­di­tion that trig­gers in­tense pain from light ex­po­sure

6 years ago
R&D
FDA+

DB­V's peanut al­ler­gy patch is fi­nal­ly un­der FDA re­view; Rit­ter swal­lows bit­ter pill to ex­plore strate­gic al­ter­na­tives

6 years ago
News Briefing

NICE fails to en­dorse Roche's Tecen­triq for breast can­cer; Eli­cio clos­es fi­nanc­ing round with $33M

6 years ago
News Briefing

For­mer Akcea pres­i­dent makes the leap to CEO seat at Avid­i­ty Bio­sciences; Astel­las in­vests $12.5M in­to two in­cu­ba­tors

6 years ago
News Briefing

Chris Roberts jumps back in­to biotech with CSO gig at Black Di­a­mond; Trou­bled Five Prime ap­points in­ter­im CEO

6 years ago
Peer Review

Am­gen inks dis­cov­ery deal with Hum­ming­bird; Mer­ck gains pri­or­i­ty re­view for Ebo­la vac­cine

6 years ago
News Briefing

As­traZeneca's di­a­betes drug grant­ed fast track des­ig­na­tion for heart fail­ure; Ver­ri­ca sends skin in­fec­tion treat­ment ...

6 years ago
News Briefing

Wood­ford forced to write down val­ues of hold­ings; No­var­tis show­cas­es pos­i­tive PhI­II MS da­ta

6 years ago
News Briefing

Alex Ar­faei trades his an­a­lyst's post for a new role as biotech VC; Sanofi vet heads to Vi­for

6 years ago
Peer Review

Randy Schatz­man jumps to the helm of an­oth­er start-up; No­vo Nordisk vet lands top post at Macrophage Phar­ma

6 years ago
Peer Review

Glob­al Blood Ther­a­peu­tics buoyed by good news from FDA; Cigna to help cov­er pricey ther­a­pies

6 years ago
News Briefing

A PhII flop trig­gers an ug­ly rout for mi­cro-cap biotech Aridis; Gen­fit CEO pass­es ba­ton to suc­ces­sor

6 years ago
News Briefing

Paratek pub­lish­es pos­i­tive PhI­II da­ta on ap­proved Nuzyra; Al­ler­gan set­tles opi­oid law­suits in two Ohio coun­ties

6 years ago
News Briefing

Ex-Al­tim­mune chief Bill En­right lands CEO role at Vac­citech; Rea­ta poach­es Al­ny­lam CFO Man­meet Soni

6 years ago
Peer Review

Es­pe­ri­on re­leas­es pos­i­tive PhII re­sults; Safe­ty warn­ings at In­dia, Chi­na man­u­fac­tur­ing sites spell trou­ble for glob­al ...

6 years ago
News Briefing

ADC Ther­a­peu­tics signs pact with Freenome; Shang­hai Hen­lius Biotech eyes $600M for Hong Kong IPO

6 years ago
News Briefing

Igny­ta founder boosts team at his new can­cer start­up; Cy­tomx CMO hits the ex­it

6 years ago
Peer Review

GSK sub­mits its first ap­pli­ca­tion for dapro­du­s­tat in Japan; Two drug­mak­ers part with $15M to avoid opi­oid tri­al

6 years ago
News Briefing
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times